You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

28 search results for: itch

<b>Itch</b>: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​

Dermatology
A review of the shared and unique neuroimmune mechanisms in the generation of itch across AD, PN, and CSU.
View more
What Drives Chronic <b>Itch</b> and the <b>Itch</b>-Scratch Cycle in Atopic Dermatitis?
videoanimation

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

Dermatology
Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
View more
<b>Itch</b>: Neuroimmune Axis in Chronic Pruritic Skin Diseases
expert video

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Dermatology
Dr. Weidinger discusses the intricate neuroinflammatory mechanisms of chronic pruritic skin disease such as AD and PN.
View more
The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
Exploring Neurosensitization and Pain in Prurigo Nodularis
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

Dermatology
Dr. Gil Yosipovitch explains that patients with PN may experience pain due to neurosensitization.
View more
The Path to Nodules: Type 2 Inflammation at the Core of Chronic <b>Itch</b> and Fibrosis in Prurigo Nodularis
expert video

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

Type 2 Inflammation
Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.
View more
IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Dermatology
Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.
View more
Neuroiflammation and Neurogenic <b>Itch</b> in Prurigo Nodularis
expert video

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Dermatology
Dr. Chovatiya discusses the neuroinflammatory mechanisms of PN.
View more
Neuroimmune Axis in Atopic Dermatitis
expert video

Neuroimmune Axis in Atopic Dermatitis

Dermatology
A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.
View more
Neuroimmune Axis and Neuroinflammation in PN
expert video

Neuroimmune Axis and Neuroinflammation in PN

Dermatology
A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.
View more
Dysbiosis, Skin Infections, and <b>Itch</b>
expert video

Dysbiosis, Skin Infections, and Itch

Dermatology
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.
View more
Role of Type 2 Inflammation in Skin Barrier Disruption and <b>Itch</b>
expert video

Role of Type 2 Inflammation in Skin Barrier Disruption and Itch

Dermatology
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region